A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma
February 26th 2018Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC). <br />